Publications by authors named "Endrin Koni"
Article Synopsis
- Higher body mass index (BMI) is a known cardiovascular risk factor, but its specific impact on complications from transcatheter aortic valve implantation (TAVI) is not fully understood.
- A study using the RISPEVA database analyzed 3776 patients, finding that those with high BMI had a 30-day risk of vascular and bleeding complications significantly greater than those with normal BMI (11.1% vs 8.8%).
- The increased rates of complications were especially pronounced within the first week post-TAVI and confirm that high BMI is an independent risk factor for adverse outcomes after the procedure.
Background: The optimal pharmacological therapy after transcatheter aortic valve implantation (TAVI) remains uncertain. We compared efficacy and safety of various antiplatelet and anticoagulant approaches after TAVI by a network meta-analysis.
Methods: A total of 14 studies (both observational and randomized) were considered, with 24,119 patients included.
Among drug-eluting stents (DESs), the durable polymer everolimus-eluting stent (EES) and resolute zotarolimus-eluting stent (R-ZES) are widely used in clinical practice and have contributed to improve the outcomes of patients undergoing percutaneous coronary intervention (PCI). Few studies addressed their long-term comparative performance in patients with acute coronary syndrome (ACS). We aimed to investigate the 5 year comparative efficacy of EES and R-ZES in ACS.
View Article and Find Full Text PDFVon Willebrand factor (VWF) is an emerging risk factor in acute coronary syndromes. Platelet Function Analyzer (PFA-100) with Collagen/Epinephrine (CEPI) is sensitive to functional alterations of VWF and also identifies patients with high on-treatment platelet reactivity (HPR). The objective of this study was to verify the effect of double dose (DD) of aspirin and clopidogrel on HPR detected by PFA-100 and its relation to VWF and to its regulatory metalloprotease ADAMTS-13.
View Article and Find Full Text PDF